Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    18171422 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
2 Recruiting Pre-operative Zoledronate in Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronate

Indicates status has not been verified in more than two years